Tumor-associated neutrophils as new players in immunosuppressive process of the tumor microenvironment in breast cancer

Hajizadeh, Farnaz; Maleki, Leili Aghebati; Марков, А. В.; Михайлова, М. В.; Masjedi, Ali; Ahmadpour, Mohammad; Hashemi, Vida; Jadidi‐Niaragh, Farhad

doi:10.1016/j.lfs.2020.118699

Cited by 62 publications

(53 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TANs are defined as CD45 + CD11b + Ly6G + and have been reported to express CD66 and CD15 in human cancers (46)(47)(48). It should be noted that the markers that have been established for TANs are indistinguishable from traditional neutrophils, with the most established phenotypic difference between the two cell groups being that neutrophils have a half-life of 6-8 hours whereas TANs have a significantly increased lifespan (an additional 12-24 hours) caused by an inhibition of apoptotic pathways and support from cytokines within the tumor microenvironment (48)(49)(50)(51)(52). Similar in nomenclature to TAMs, TANs can also be divided into N1 pro-inflammatory and N2 pro-tumor subtypes, however due to limitations in markers there is not an established panel for differentiating N1 from N2 TANs (46).…”

Section: The Tumor Microenvironment and Tumor Associated Immune Cellsmentioning

confidence: 99%

“…For TAMs, this includes producing anti-inflammatory mediators such as IL-10, Arg1, and TGF-b (56)(57)(58), promoting the expression of checkpoint inhibitors to suppress T cells (56,57), inducing cancer stem cell proliferation via IL-6 signaling through STAT3 (59), and producing VEGF to stimulate angiogenesis (60,61). These effects are also seen in TANs and MDSCs, which have both been shown to produce similar profiles of cytokines, checkpoint inhibitors, and growth factors (47,48,(62)(63)(64).…”

Section: The Tumor Microenvironment and Tumor Associated Immune Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Immunological Effects of Histotripsy for Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

Cancer is the second leading cause of death worldwide despite major advancements in diagnosis and therapy over the past century. One of the most debilitating aspects of cancer is the burden brought on by metastatic disease. Therefore, an ideal treatment protocol would address not only debulking larger primary tumors but also circulating tumor cells and distant metastases. To address this need, the use of immune modulating therapies has become a pillar in the oncology armamentarium. A therapeutic option that has recently emerged is the use of focal ablation therapies that can destroy a tumor through various physical or mechanical mechanisms and release a cellular lysate with the potential to stimulate an immune response. Histotripsy is a non-invasive, non-ionizing, non-thermal, ultrasound guided ablation technology that has shown promise over the past decade as a debulking therapy. As histotripsy therapies have developed, the full picture of the accompanying immune response has revealed a wide range of immunogenic mechanisms that include DAMP and anti-tumor mediator release, changes in local cellular immune populations, development of a systemic immune response, and therapeutic synergism with the inclusion of checkpoint inhibitor therapies. These studies also suggest that there is an immune effect from histotripsy therapies across multiple murine tumor types that may be reproducible. Overall, the effects of histotripsy on tumors show a positive effect on immunomodulation.

show abstract

Section: The Tumor Microenvironment and Tumor Associated Immune Cellsmentioning

confidence: 99%

Section: The Tumor Microenvironment and Tumor Associated Immune Cellsmentioning

confidence: 99%

Immunological Effects of Histotripsy for Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Compared with neutrophils in blood, tumor associated neutrophils (TANs) around tumor can produce more cytokines and promote tumor progression by ways of secreting Matrix Metallopeptidase 9 (MMP-9) to advance the degradation of extracellular matrix and release vascular endothelial growth [ 94 , 95 ]. Several studies on breast cancer have found that T cells can regulate TANs and promote lung metastasis of breast cancer while neutrophils were found to be accumulated in the lungs before metastasis [ 96 , 97 ]. A study on melanoma with lung metastasis suggested that TANs can assist encapsulated tumor cells in escaping immune surveillance and these tumor cells are more likely to metastasize than scattered tumor cells [ 98 ].…”

Section: Discussionmentioning

confidence: 99%

The Clinical Significance and Potential Molecular Mechanism of Upregulated CDC28 Protein Kinase Regulatory Subunit 1B in Osteosarcoma

Xie

Chen

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Background. CDC28 Protein Kinase Regulatory Subunit 1B (CKS1B) is a member of cyclin-dependent kinase subfamily and the relationship between CKS1B and osteosarcoma (OS) remains to be explored. Methods. 80 OS and 41 nontumor tissue samples were arranged to conduct immunohistochemistry (IHC) to evaluate CKS1B expression between OS and nontumor samples. The standard mean deviation (SMD) was calculated based on in-house IHC and tissue microarrays and exterior high-throughput datasets for further verification of CKS1B expression in OS. The effect of CKS1B expression on clinicopathological and overall survival of OS patients was measured through public high-throughput datasets, and analysis of immune infiltration and single-cell RNA-seq was applied to ascertain molecular mechanism of CKS1B in OS. Results. A total of 197 OS samples and 83 nontumor samples (including tissue and cell line) were obtained from in-house IHC, microarrays, and exterior high-throughput datasets. The analysis of integrated expression status demonstrated upregulation of CKS1B in OS (SMD = 1.38, 95% CI [0.52–2.25]) and the significant power of CKS1B expression in distinguishing OS samples from nontumor samples (Area under the Curve (AUC) = 0.89, 95% CI [0.86–0.91]). Clinicopathological and prognosis analysis indicated no remarkable significance but inference of immune infiltration and single-cell RNA-seq prompted that OS patients with overexpressed CKS1B were more likely to suffer OS metastasis while MYC Protooncogene may be the upstream regulon of CKS1B in proliferating osteoblastic OS cells. Conclusions. In this study, sufficient evidence was provided for upregulation of CKS1B in OS. The advanced effect of CKS1B on OS progression indicates a foreground of CKS1B as a biomarker for OS.

show abstract

“…13 In addition, there is a large amount of tumor-associated neutrophils (TANs) in the TME, which facilitates the continuous recruitment of circulating neutrophils towards tumor tissues. 14 However, most drugs cannot be directly carried by neutrophils because of their cytotoxicity to cells. Therefore, loading nanomaterial-encapsulated drugs into neutrophils appears to be an effective solution to overcome this obstacle, which not only attenuates the nanotoxicity of DDSs, but also avoids their immune clearance.…”

Section: Introductionmentioning

confidence: 99%